|By Marketwired .||
|July 25, 2014 08:05 AM EDT||
CEDAR KNOLLS, NJ -- (Marketwired) -- 07/25/14 -- MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has signed an extension of its supply agreement with Deutsches Institut fuer Lebensmitteltechnik e.V ("DIL"), the German Institute for Food Technologies, for the continued manufacturing and supply of Fortetropin, the first clinically proven natural myostatin inhibitor. DIL is a world leader in developing and providing the finest products in food technology today.
Under the terms of the agreement, DIL will manufacture and supply Fortetropin exclusively for MYOS through the end of 2016 with a significant cost-savings component. The supply relationship maintains the stable, world-class manufacturing and supply of Fortetropin, the primary proprietary ingredient in MYOS' core muscle health bionutrition supplement products. Fortetropin is produced using a proprietary method in accordance with the highest industry standards, incorporating DIL's state of the art High Pressure Pasteurization (HPP) technology for preserving the high quality freshness of the natural ingredients. Use of the proprietary manufacturing process at DIL's cutting edge facilities ensures the continued efficacy and quality of Fortetropin. The Supply Agreement extension also requires ongoing adherence to the highest levels of product testing.
"The execution of the supply extension renews the strategic relationship we have with DIL and our commitment to providing our customers with the highest quality bionutrition products," commented Peter Levy, President and Chief Operating Officer of MYOS. "Our Fortetropin-based products are scientifically proven to build lean muscle, and are arguably the best tasting dietary supplements on the market today. Continued production by DIL provides our customers the assurance that they can expect the finest nutritional product in muscle health."
About MYOS Corporation
MYOS is a developmental stage biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin (MYO-T12®), the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company," visit www.myoscorp.com.
The Company's first commercial product based on Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin (MYO-T12®) and its effects on myostatin inhibition, including our research and development activities, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, the expansion of our biotherapeutic development pipeline, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
MYOS Corporation Investor and Media Contact:
Investor Relations and Corporate Communications
Mar. 25, 2017 05:30 AM EDT Reads: 1,318
Mar. 25, 2017 05:00 AM EDT Reads: 10,811
Mar. 25, 2017 05:00 AM EDT Reads: 9,614
Mar. 25, 2017 05:00 AM EDT Reads: 5,909
Mar. 25, 2017 03:00 AM EDT Reads: 5,647
Mar. 25, 2017 02:00 AM EDT Reads: 2,781
Mar. 25, 2017 01:45 AM EDT Reads: 1,421
Mar. 25, 2017 12:15 AM EDT Reads: 1,562
Mar. 25, 2017 12:00 AM EDT Reads: 484
Mar. 24, 2017 11:45 PM EDT Reads: 643
Mar. 24, 2017 11:15 PM EDT Reads: 2,494
Mar. 24, 2017 10:15 PM EDT Reads: 4,148
Mar. 24, 2017 10:00 PM EDT Reads: 1,884
Mar. 24, 2017 08:15 PM EDT Reads: 318
Mar. 24, 2017 06:30 PM EDT Reads: 2,622